Michael A. Robinson
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance, and Nexus-9 Network.
Michael'S LATEST HEADLINES
- Biotech (and Its IPOs) Will Crush Records in 2020 – Here's How to Profit
I'll come right out and say it: Every investor should be doing their level best to position themselves at the epicenter of biotechnology – pharmaceuticals – right now.
These stocks are leading a soaring stock market, particularly the NASDAQ Composite, which is at all-time highs. Of the index's 10 biggest gainers at midday yesterday, half were biotechs.
Obviously, the race to find a vaccine or even a proven therapy for the novel coronavirus pandemic is a huge driver of the profits here. My paid subscribers recently got the chance to book 375% gains on half of one of our vaccine research plays, and took 70% in profits on another.
But there's much more going on.
The sheer amount and volume of capital pouring into this sector like a firehose – it's nothing short of breathtaking.
I'm going to show you my favorite, low-risk way to tap that immense growth.
But first, you have to see some of these numbers… Full Story
But first, you have to see some of these numbers... - Why This Defense Sector Play Is a Buy Now
- One of the Biggest Mergers in Defense History Created This "Must Buy" Security Play
- This Aerospace Powerhouse Will Double Your Money (and Seriously Upgrade Your Vacations)
- This Technology Will Fuel Hundreds of Billions in Cannabis Profits
- Here's a High-Profit "Kicker" for Your Microsoft Stock
- You Can Invest Alongside One of the Savviest Tech Players of All Time
- A Tech Insider's Pick to Play This "Must Own" Slice of the Future
- This One Company Is Like Your Own Personal Tech ETF
- One Firm Is Taking the Hassle Out of Digital Payments – and Handing You a Piece of an $11 Trillion Opportunity